Episode
Amit Etkin: Precision Psychiatry’s Future Isn’t Genomics—It’s Brain Activity
- Podcast
- Behind the Breakthroughs
- Published
- Jul 15, 2026
- Duration seconds
- 3632
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-breakthroughs-7055075/episodes/amit-etkin-precision-psychiatry-s-future-isn-t-genomics-it-s-brain-activity/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-breakthroughs-7055075/amit-etkin-precision-psychiatry-s-future-isn-t-genomics-it-s-brain-activity.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of Behind the Breakthroughs , Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biologically defined patient populations could make precision psychiatry routine, improving outcomes and changing how psychiatric disorders are diagnosed and treated. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.